UPDATED: As PDUFA looms Sanofi punts a $35M partnership

A little more than a year after Sanofi ($SNY) stepped in to sign a development deal with Pozen, the pharma giant has stepped back out just weeks ahead of a scheduled PDUFA date. Chapel Hill, NC-based Pozen ($POZN) says the pharma giant and the biotech "mutually agreed" to end the partnership to develop a pair of new-and-improved aspirins dubbed PA8140 and PA32540. Sanofi paid $15 million in cash and promised up to $20 million more in precommercialization milestones to get the deal. Pozen CEO John Plachetka said the company would consider its strategic options, noting the drug is tackling a target market with more than 20 million consumers. Investors, though, weren't too happy with today's turn of events. Pozen's shares plunged 19% in morning trading. Pozen also has commercial names in place. PA8140 will be referred to as YOSPRALA 81/40 (enteric-coated aspirin 81 mg/immediate release omeprazole 40 mg) and PA32540 (enteric-coated aspirin 325 mg/immediate release omeprazole 40 mg) will be referred to as YOSPRALA 325/40. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.